Morgan Stanley Downgrades Akoya Biosciences to Equalweight From Overweight, Adjusts PT to $3 From $4
Morgan Stanley Downgrades Akoya Biosciences to Equalweight From Overweight, Adjusts PT to $3 From $4
摩根士丹利将Akoya Biosciences的评级下调至等重，从超重调整目标价为3美元，而不是4美元。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间